Naiyer A. Rizvi, MD

Dr. Rizvi is the Price Family Professor of Medicine and Director of Thoracic Oncology as well as Co-Director of Cancer Immunotherapy at Columbia University Irving Medical Center. He is also the Research Director of the Price Family Comprehensive Center for Chest Care at New York-Presbyterian Hospital.
He is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. His early clinical trial research played a significant role in the FDA approval of immune checkpoint inhibitors, for melanoma and lung cancer. His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients and why others do not respond.
He conducts clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer. He receives funding from the National Institute of Health and Stand Up to Cancer for his research and his work has been published in high impact journals including Science, Nature and New England Journal of Medicine.